Leserbrief zum Beitrag: „Ondansetron: 5-HT3-Antagonist, kein notfallpharmakologisches Universalantiemetikum“

• Literatur

• 1 Ittner K, Leberle R, Neubert A. et al. Ondansetron: 5-HT3-Antagonist, kein notfallpharmakologisches Universalantiemetikum. NOTARZT 2023; 39: 240-244
• 2 Gottlieb M, Carlson JN, Peksa GD. Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting. Cochrane Database Syst Rev 2022; (05) CD013860
• 3 European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. 06.02.2014 Accessed January 18, 2024 at: https://www.ema.europa.eu/en/medicines/human/referrals/metoclopramide-containing-medicines#:~:text=During%20the%20re%2Dexamination%20the,second%2Dchoice%20treatment%20(after%20other
• 4 Panpharma. Fachinformation. Droperidol Panpharma 2,5 mg/ml Injektionslösung. 2019 Accessed February 12, 2024 at: https://www.fachinfo.de/api/public/fachinfo/pdf/020757
• 5 ratiopharm. Fachinformation. Haloperidol-ratiopharm® 5 mg Injektionslösung. 2021 Accessed February 12, 2024 at: https://www.fachinfo.de/api/public/fachinfo/pdf/010782
• 6 Furyk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. Cochrane Database Syst Rev 2015; (09) CD010106
• 7 Philpott L, Clemensen E, Lau GT. Droperidol versus ondansetron for nausea treatment within the emergency department. Emerg Med Australas 2023; 35: 605-611
• 8 Shahsavari D, Reznick-Lipina K, Malik Z. et al. Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. Clin Transl Gastroenterol 2021; 12: e00362
• 9 Ruberto AJ, Sivilotti MLA, Forrester S. et al. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. Ann Emerg Med 2021; 77: 613-619
• 10 Sabbineni M, Scott W, Punia K. et al. Dopamine antagonists and topical capsaicin for cannabis hyperemesis syndrome (CHS) in the emergency department: a systematic review of direct evidence. Acad Emerg Med 2023;
• 11 Miller JL, Ashford JW, Archer SM. et al. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. Pharmacotherapy 2008; 28: 875-882
• 12 Cisewski D, Long B, Gottlieb M. Emergency medicine updates: Droperidol. Am J Emerg Med 2022; 53: 180-184
• 13 Burns JR, Kram JJF, Xiong V. et al. Utilization of Acupuncture Services in the Emergency Department Setting: A Quality Improvement Study. J Patient Cent Res Rev 2019; 6: 172-178